New Cell Therapy Program to Offer Hope for Patients With Severe Lupus
Yale Health & Medicine News,
Since 2015, the Yale Lupus Program has conducted clinical and translational research to better understand the causes of lupus…
Since 2015, the Yale Lupus Program has conducted clinical and translational research to better understand the causes of lupus…
January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
NEW YORK, NY. January 27 -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ The Lupus Research Alliance (LRA) and…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The (LRA) and its clinical…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
Announces Appointment of New Health Equity Director, /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director Published: Jan. 27, 2022 at 1:31 PM CST|Updated: 6 minutes ago NEW YORK, Jan.
Announces Appointment of New Health Equity Director Published: Jan. 27, 2022 at 2:31 PM EST|Updated: 6 minutes ago NEW YORK, Jan.
Announces Appointment of New Health Equity Director Published: Jan. 27, 2022 at 2:31 PM EST|Updated: 6 minutes ago NEW YORK, Jan.
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The (LRA) and its clinical affiliate (LT) announced two major initiatives to address…
Announces Appointment of New Health Equity Director Published: Jan. 27, 2022 at 1:31 PM CST|Updated: 5 minutes ago NEW YORK, Jan.
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The (LRA) and its clinical affiliate (LT) announced two major initiatives to address…
Announces Appointment of New Health Equity Director Published: Jan. 27, 2022 at 1:31 PM CST|Updated: moments ago NEW YORK, Jan.
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
Announces Appointment of New Health Equity Director Published: Jan. 27, 2022 at 2:31 PM EST|Updated: moments ago NEW YORK, Jan.
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The (LRA) and its clinical…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The (LRA) and its clinical…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The Lupus Research Alliance (LRA…
Announces Appointment of New Health Equity Director NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The (LRA) and its clinical…
NEW YORK, Jan. 27, 2022 /PRNewswire/ -- The (LRA) and its clinical affiliate (LT) announced two major initiatives to address…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
Norwood, MA, April 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc.
First study to explore potential benefit of a cannabinoid receptor type 2 agonist inSLEStudysponsored andfundedby…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s…
Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests ALBUQUERQUE, NM and SAN DIEGO, CA…
Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests ALBUQUERQUE, NM and SAN DIEGO, CA…
ALBUQUERQUE, NM and SAN DIEGO, CA, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life sciences…
GlobeNewswire 2018-10-12 Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests…
Cent-deux personnes souffrant de lupus ont été randomisées pour recevoir de l'ustekinumab ou un placebo.
(HealthDay News) -- Systemic lupus erythematous (SLE) is among the top 20 leading causes of death in females between the ages…
-- Systemic lupus erythematous (SLE) is among the top 20 leading causes of death in females between the ages of 5 and 64 years…
Death from lupus ranked 10th in women 15 to 24 years, 14th in those aged 25 to 34 and 35 to 44 years HealthDay News — Systemic…
Dans le lupus érythémateux disséminé (LED), une nouvelle étude montre que le belimumab, un anticorps monoclonal ciblant le BLyS…
New research indicates that belimumab, a monoclonal antibody therapy that targets a component of the immune system, provides…
New research indicates that belimumab, a monoclonal antibody therapy that targets a component of the immune system, provides…
New research indicates that belimumab, a monoclonal antibody therapy that targets a component of the immune system, provides…